Published in Nephrology (Carlton) on February 01, 2007
Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology (2008) 2.31
Kidney-derived stromal cells modulate dendritic and T cell responses. J Am Soc Nephrol (2009) 1.51
Adipose tissue-derived mesenchymal stem cells improve revascularization outcomes to restore renal function in swine atherosclerotic renal artery stenosis. Stem Cells (2012) 1.44
Autologous and allogeneic marrow stromal cells are safe and effective for the treatment of acute kidney injury. Stem Cells Dev (2009) 1.41
Fgf9 signaling regulates small intestinal elongation and mesenchymal development. Development (2008) 1.15
Mesenchymal stem cells: from experiment to clinic. Fibrogenesis Tissue Repair (2011) 1.13
The allogeneic umbilical cord mesenchymal stem cells regulate the function of T helper 17 cells from patients with rheumatoid arthritis in an in vitro co-culture system. BMC Musculoskelet Disord (2012) 0.92
Safety and efficacy of intravenous infusion of allogeneic cryopreserved mesenchymal stem cells for treatment of chronic kidney disease in cats: results of three sequential pilot studies. Stem Cell Res Ther (2013) 0.90
Immune system in renal injury and repair: burning the candle from both ends? Pharmacol Res (2008) 0.81
Differential Expression of Insulin-Like Growth Factor-I Receptor on Human Bone Marrow-Derived Mesenchymal Stem Cells Induced by Tumor Necrosis Factor-α. Int J Organ Transplant Med (2014) 0.77
Mesenchymal stem cells as a therapeutic approach to glomerular diseases: benefits and risks. Kidney Int Suppl (2011) (2011) 0.77
Stem cell-based regenerative opportunities for the liver: State of the art and beyond. World J Gastroenterol (2015) 0.77
Approaches to avoid immune responses induced by repeated subcutaneous injections of allogeneic umbilical cord tissue-derived cells. Transplantation (2010) 0.75
Vitamin D analog EB1089 could repair the defective bone marrow-derived mesenchymal stromal cells in patients with systemic lupus erythematosus. Int J Clin Exp Med (2015) 0.75
Composite tissue allotransplantation and dysregulation in tissue repair and regeneration: a role for mesenchymal stem cells. Front Immunol (2013) 0.75
Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant (2005) 2.82
Molecular trafficking mechanisms of multipotent mesenchymal stem cells derived from human bone marrow and placenta. Stem Cells Dev (2008) 2.24
Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells. Stem Cells Dev (2008) 1.74
Therapeutic applications of mesenchymal stromal cells. Semin Cell Dev Biol (2007) 1.52
Comprehensive transcriptome and immunophenotype analysis of renal and cardiac MSC-like populations supports strong congruence with bone marrow MSC despite maintenance of distinct identities. Stem Cell Res (2011) 1.45
Manufacturing of human placenta-derived mesenchymal stem cells for clinical trials. Br J Haematol (2008) 1.39
Molecular mechanisms involved in mesenchymal stem cell migration to the site of acute myocardial infarction. Int J Cell Biol (2009) 0.99
Immunological properties of extraembryonic human mesenchymal stromal cells derived from gestational tissue. Stem Cells Dev (2013) 0.95
Micromarrows--three-dimensional coculture of hematopoietic stem cells and mesenchymal stromal cells. Tissue Eng Part C Methods (2012) 0.89
Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease. Transplantation (2008) 0.88
Examination of the regulatory frameworks applicable to biologic drugs (including stem cells and their progeny) in Europe, the U.S., and Australia: part I--a method of manual documentary analysis. Stem Cells Transl Med (2012) 0.84
Points to Consider in Designing Mesenchymal Stem Cell-Based Clinical Trials. Transfus Med Hemother (2008) 0.84
Evaluation of methods for cultivating limbal mesenchymal stromal cells. Cytotherapy (2012) 0.83
Mesenchymal stromal cells transiently alter the inflammatory milieu post-transplant to delay graft-versus-host disease. Haematologica (2010) 0.82
Manufacturing and use of human placenta-derived mesenchymal stromal cells for phase I clinical trials: establishment and evaluation of a protocol. Vojnosanit Pregl (2014) 0.81
Examination of the regulatory frameworks applicable to biologic drugs (including stem cells and their progeny) in Europe, the U.S., and Australia: part II--a method of software documentary analysis. Stem Cells Transl Med (2012) 0.81
The ascorbic acid paradox. Biochem Biophys Res Commun (2010) 0.81
Membrane bioreactors enhance microenvironmental conditioning and tissue development. Tissue Eng Part C Methods (2010) 0.79
Bioreactor for blood product production. Cell Transplant (2012) 0.78
Manufacture of clinical grade human placenta-derived multipotent mesenchymal stromal cells. Methods Mol Biol (2011) 0.78
Cellular therapy for repair of cardiac damage after acute myocardial infarction. Int J Cell Biol (2009) 0.77